Trehalose (autophagy inducer)

autophagy mitophagy

Sold as a consumer product in 1 of 9 markets tracked.

Evidence so far is from 1 human trial with no pre-planned main endpoint and animal studies.

In people: 1 trial (32 people, 12 weeks). Doses studied: 100 g/day.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (4)

T7 Kaplon 2016 Oral trehalose supplementation improves resistance artery endothelial function in healthy middle-aged and older adults doi:10.18632/aging.100962
T3 Xi 2024 Trehalose Alleviates D-Galactose-Induced Aging-Related Granulosa Cell Death in Ovaries doi:10.3390/ijms252312643
T3 Gong 2022 Trehalose inhibits ferroptosis via NRF2/HO-1 pathway and promotes functional recovery in mice with spinal cord injury doi:10.18632/aging.204009
TX Chmielewski 2024 Mitigating Glycation and Oxidative Stress in Aesthetic Medicine: Hyaluronic Acid and Trehalose Synergy for Anti-AGEs Action in Skin Aging Treatment doi:10.2147/ccid.s476362